drugset / Trial / NCT00277758
Safety Study of Low Dose Interleukin 2 (IL-2) Plus PEG-IFN/RBV In Chronic Hepatitis C Virus Genotype I
Phase 1
Terminated
18 enrolled
Weill Medical College of Cornell University
National Institute of Allergy and Infectious Diseases (NIAID) · collab
RandomizedSingle-groupOpen-labelTreatment
Summary
This is a treatment study trial, in which we will assess the safety and tolerability of daily dose IL-2, as monotherapy for 12 weeks, followed by IL2 in combination with PEG-IFN and RBV for 48 weeks in the treatment of chronic Hepatitis C.
Timeline
- Start
- 2004-03
- Primary completion
- 2006-07
- Completion
- 2006-08
Outcome
Outcome not reported
Stopped (Enrollment): “Insufficient rate of volunteer accrual.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | aldesleukin | Protein / enzyme biologic | 1.2 unknown | Subcutaneous |
| Background | Pegylated Interferon-alpha | Protein / enzyme biologic | 1.5 ug/kg | Subcutaneous |
| Background | Ribavirin | Small molecule | 800 mg | — |
| Background | Ribavirin | Small molecule | 1000 mg | — |
| Background | Ribavirin | Small molecule | 1200 mg | — |